Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Co-Diagnostics
CODX
Co-Diagnostics
Clinical Advancements And Cloud Integration Will Shape Molecular Diagnostics
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
04 May 25
Updated
24 Jul 25
4
Set Fair Value
0
votes
1
Share
AnalystConsensusTarget
's Fair Value
US$5.50
95.5% undervalued
intrinsic discount
24 Jul
US$0.25
Loading
1Y
-75.8%
7D
-4.6%
Author's Valuation
US$5.5
95.5% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
US$5.5
95.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-96m
96m
2014
2017
2020
2023
2025
2026
2028
Revenue US$81.9m
Earnings US$9.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
70.26%
Medical Equipment revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.97%
Calculation
US$9.67m
Earnings '28
x
27.55x
PE Ratio '28
=
US$266.30m
Market Cap '28
US$266.30m
Market Cap '28
/
39.75m
No. shares '28
=
US$6.70
Share Price '28
US$6.70
Share Price '28
Discounted to 2025 @ 7.48% p.a.
=
US$5.40
Fair Value '25